News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study     8/13/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar     5/16/2012
Argos Therapeutics, Inc. Raises $25 Million Series D Financing     4/24/2012
AVEO Pharmaceuticals, Inc. (AVEO) Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology     4/12/2012
FDA Approves Pfizer Inc. (PFE)'s INLYTA® (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)     1/30/2012
Pfizer Inc. (PFE) Receives Backing for Late-stage Trial of Kidney Cancer Drug in Asia     1/9/2012
Pfizer Inc. (PFE) Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)     11/19/2010
GlaxoSmithKline (GSK) (JOBS) Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)     10/7/2009
Novartis AG Release: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib     3/31/2009
Oxford BioMedica PLC (OXB.L) Announces Data Safety Monitoring Board Recommendation to Continue Phase 3 Study; Achievement Triggers €10 M Milestone Payment from Sanofi-Aventis (France) (SASY.PA)     2/20/2008

News from Around the Web

Press Releases
TRACON Pharmaceuticals, Inc. (TCON)'s TRC105 Receives FDA Fast Track Designation     5/15/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Enrollment Progress For Ongoing Pivotal Phase III ADAPT Clinical Trial     5/14/2015
Cerulean Pharma Inc. (CERU) Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma     4/28/2015
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC)     4/21/2015
Peloton Therapeutics Presents Promising Data On First Inhibitor Of HIF-2a For Renal Cell Carcinoma At 2015 AACR Annual Meeting     4/20/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma     4/9/2015
Cerulean Pharma Inc. (CERU) Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin In Relapsed Renal Cell Carcinoma Meets Primary Endpoint     3/20/2015
Celldex (CLDX) Announces Clinical Trial Collaboration With Roche (RHHBY) To Evaluate The Combination Of Varlilumab And MPDL3280A     3/17/2015
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma     12/15/2014
TRACON Pharmaceuticals, Inc. Initiates Randomized Phase 2 Clinical Trial Of TRC105 In Patients With Renal Cell Carcinoma     12/1/2014
Enrollment In Argos Therapeutics, Inc. (ARGS)' Pivotal Phase 3 ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent     9/18/2014
Cerulean Pharma Inc. (CERU) Announces CRLX101 Combination Data At 2014 American Society of Clinical Oncology Annual Meeting     6/3/2014
Argos Therapeutics, Inc. (ARGS) Release: Treatment With AGS-003 And Sunitinib Associated With Doubling Of Expected Survival In Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)     6/2/2014
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2)     5/30/2014
Rexahn Pharmaceuticals, Inc. (RNN) Initiates Phase 2a Clinical Trial Of Archexin® In Patients With Metastatic Renal Cell Carcinoma     1/14/2014

//-->